A carcinoma that arises from the intrahepatic bile duct epithelium in any site of the intrahepatic biliary tree. Grossly, the malignant lesions are solid, nodular, and grayish. Morphologically, the va...
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
The documentation on intrahepatic cholangiocarcinoma is limited due to its rarity and the challenges associated with studying such a small patient population. As ICC affects fewer individuals compared to more common cancers, systematic clinical studies have been sparse. Furthermore, the complex nature of this disease, including overlapping symptoms with other conditions, complicates the clinical characterization.
To navigate your care effectively, it is advisable to seek a specialist in gastrointestinal oncology who has experience with rare bile duct cancers. You can also explore clinical trials that may be available to you, which could provide access to cutting-edge therapies. For additional resources, consider visiting the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov. While there are currently no patient organizations identified specifically for intrahepatic cholangiocarcinoma, engaging with broader cancer support networks may provide valuable community support.
There are currently 122 active clinical trials investigating various aspects of intrahepatic cholangiocarcinoma. Notably, two FDA-approved treatments are available: ivosidenib and pemigatinib. Additionally, several orphan drugs are in development, including a range of targeted therapies and antibody-drug conjugates. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=intrahepatic%20cholangiocarcinoma.
Actionable guidance for navigating care for intrahepatic cholangiocarcinoma
To navigate your care effectively, it is advisable to seek a specialist in gastrointestinal oncology who has experience with rare bile duct cancers. You can also explore clinical trials that may be available to you, which could provide access to cutting-edge therapies. For additional resources, consider visiting the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov. While there are currently no patient organizations identified specifically for intrahepatic cholangiocarcinoma, engaging with broader cancer support networks may provide valuable community support.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning intrahepatic cholangiocarcinoma
Updated Feb 5, 2026
A narrative review discusses the surgical management of intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma, highlighting principles, technical nuances, and emerging strategies. This review provides insights into evolving surgical techniques that may improve patient outcomes.